Biohaven (NYSE:BHVN) Stock Price Up 6.6% – Still a Buy?

Posted by George Bondi on Aug 25th, 2026

Biohaven Ltd. (NYSE:BHVN – Get Free Report) rose 6.6% on Tuesday . The company traded as high as $14.49 and last traded at $14.5850. Approximately 379,458 shares changed hands during mid-day trading, a decline of 85% from the average session volume of 2,540,132 shares. The stock had previously closed at $13.68.

Wall Street Analyst Weigh In

Several research firms recently issued reports on BHVN. Bank of America restated an “underperform” rating and set a $11.00 price target (down from $12.00) on shares of Biohaven in a research report on Monday, June 29th. Weiss Ratings reiterated a “sell (e+)” rating on shares of Biohaven in a research report on Tuesday, June 2nd. HC Wainwright reissued a “neutral” rating and set a $10.00 price objective on shares of Biohaven in a research note on Tuesday, May 26th. Royal Bank Of Canada raised their target price on shares of Biohaven from $22.00 to $23.00 and gave the stock an “outperform” rating in a report on Tuesday, August 11th. Finally, Needham & Company LLC set a $11.00 target price on shares of Biohaven in a research note on Monday, June 29th. Two research analysts have rated the stock with a Strong Buy rating, nine have given a Buy rating, four have given a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $21.75.

Get Our Latest Research Report on Biohaven

Biohaven Price Performance

The company has a debt-to-equity ratio of 21.23, a quick ratio of 4.73 and a current ratio of 4.73. The business has a 50-day simple moving average of $14.62 and a 200 day simple moving average of $11.76. The firm has a market cap of $2.17 billion, a P/E ratio of -3.10 and a beta of 1.26.

Biohaven (NYSE:BHVN – Get Free Report) last posted its earnings results on Monday, August 10th. The company reported ($0.91) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.76) by ($0.15). On average, analysts anticipate that Biohaven Ltd. will post -3.29 earnings per share for the current fiscal year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently made changes to their positions in the company. PNC Financial Services Group Inc. raised its holdings in Biohaven by 113.7% in the third quarter. PNC Financial Services Group Inc. now owns 2,383 shares of the company’s stock worth $36,000 after purchasing an additional 1,268 shares in the last quarter. IFP Advisors Inc increased its stake in Biohaven by 55.4% during the 4th quarter. IFP Advisors Inc now owns 4,069 shares of the company’s stock valued at $46,000 after purchasing an additional 1,450 shares in the last quarter. EverSource Wealth Advisors LLC increased its position in shares of Biohaven by 178.4% during the fourth quarter. EverSource Wealth Advisors LLC now owns 4,031 shares of the company’s stock valued at $46,000 after acquiring an additional 2,583 shares in the last quarter. Arax Advisory Partners raised its stake in shares of Biohaven by 943.3% in the fourth quarter. Arax Advisory Partners now owns 4,914 shares of the company’s stock worth $55,000 after purchasing an additional 4,443 shares during the last quarter. Finally, Essential Partners LLC raised its position in Biohaven by 31.7% in the 1st quarter. Essential Partners LLC now owns 9,020 shares of the company’s stock worth $76,000 after buying an additional 2,169 shares during the last quarter. Hedge funds and other institutional investors own 88.78% of the company’s stock.

Biohaven Company Profile

(Get Free Report)

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company’s most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.